FDA final rule puts question mark over future of intercentre agreements
This article was originally published in Clinica
Executive Summary
The US FDA may abolish its intercentre agreements, the agency disclosed last week in a largely uneventful final rule establishing a procedure for deciding which centre should have regulatory responsibility for a combination product.